3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
79
Neoplasms
9
Carcinoma, Intraductal, Noninfiltrating
5
Breast Neoplasms, Male
4
Neoplasm Metastasis
3
Breast Carcinoma In Situ
3
Arthralgia
3
Triple Negative Breast Neoplasms
2
Sexual Dysfunction, Physiological
1
Seizures
1
Recurrence
1
Pain
1
Osteoporosis
1
Obesity
1
Multiple Endocrine Neoplasia Type 1
1
Lethal Congenital Contracture Syndrome 2
1
Joint Diseases
1
Invasive Breast Cancer
1
Hypogonadism
1
Granulosa Cell Ovarian Cancer
1
Fractures, Bone
1
Erectile Dysfunction
1
Epilepsy
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Metastatic
1
Advanced Metastatic Breast Cancer
1
Advanced Breast Carcinoma
1
Interventions
tusamitamab ravtansine
1
nirogacestat
1
exemestane
1
Tamoxifen
1
Letrozole
1
Gemcitabine
1
Fulvestrant
1
Docetaxel
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Breast Cancer Metastatic
×
Anastrozole
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts